Omzet 2024 * | 17,57 mln. 16,41 mln. | Omzet 2025 * | 29,87 mln. 27,89 mln. | Marktkapitalisatie | 52,58 mln. 49,1 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -35 mln. -32,69 mln. | Nettowinst (verlies) 2025 * | -16 mln. -14,94 mln. | EV/omzet 2024 * | 2,99 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,76 x |
K/w-verhouding 2024 * |
-2,19
x | K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 100% |
Recentste transcriptie over BioLineRX Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 24-05-09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01-01-09 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24-02-14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01-01-10 |
Aharon Schwartz
CHM | Chairman | 80 | 01-01-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,45% | 122 mld. | |
+21,96% | 116 mld. | |
+23,73% | 27,03 mld. | |
-20,05% | 20,36 mld. | |
-16,28% | 15,91 mld. | |
-16,52% | 16,43 mld. | |
-44,35% | 15,6 mld. | |
+63,91% | 14,94 mld. | |
+2,52% | 13,59 mld. |